Albert J Czaja1. 1. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Abstract
BACKGROUND: Disturbances in iron regulation have been described in diverse chronic liver diseases other than hereditary haemochromatosis, and iron toxicity may worsen liver injury and outcome. AIMS: To describe manifestations and consequences of iron dysregulation in chronic liver diseases apart from hereditary haemochromatosis and to encourage investigations that clarify pathogenic mechanisms, define risk thresholds for iron toxicity, and direct management METHODS: English abstracts were identified in PubMed by multiple search terms. Full length articles were selected for review, and secondary and tertiary bibliographies were developed. RESULTS: Hyperferritinemia is present in 4%-65% of patients with non-alcoholic fatty liver disease, autoimmune hepatitis, chronic viral hepatitis, or alcoholic liver disease, and hepatic iron content is increased in 11%-52%. Heterozygosity for the C282Y mutation is present in 17%-48%, but this has not uniformly distinguished patients with adverse outcomes. An inappropriately low serum hepcidin level has characterised most chronic liver diseases with the exception of non-alcoholic fatty liver disease, and the finding has been associated mainly with suppression of transcriptional activity of the hepcidin gene. Iron overload has been associated with oxidative stress, advanced fibrosis and decreased survival, and promising therapies beyond phlebotomy and oral iron chelation have included hepcidin agonists. CONCLUSIONS: Iron dysregulation is common in chronic liver diseases other than hereditary haemochromatosis, and has been associated with liver toxicity and poor prognosis. Further evaluation of iron overload as a co-morbid factor should identify the key pathogenic disturbances, establish the risk threshold for iron toxicity, and promote molecular interventions.
BACKGROUND: Disturbances in iron regulation have been described in diverse chronic liver diseases other than hereditary haemochromatosis, and irontoxicity may worsen liver injury and outcome. AIMS: To describe manifestations and consequences of iron dysregulation in chronic liver diseases apart from hereditary haemochromatosis and to encourage investigations that clarify pathogenic mechanisms, define risk thresholds for irontoxicity, and direct management METHODS: English abstracts were identified in PubMed by multiple search terms. Full length articles were selected for review, and secondary and tertiary bibliographies were developed. RESULTS:Hyperferritinemia is present in 4%-65% of patients with non-alcoholic fatty liver disease, autoimmune hepatitis, chronic viral hepatitis, or alcoholic liver disease, and hepatic iron content is increased in 11%-52%. Heterozygosity for the C282Y mutation is present in 17%-48%, but this has not uniformly distinguished patients with adverse outcomes. An inappropriately low serum hepcidin level has characterised most chronic liver diseases with the exception of non-alcoholic fatty liver disease, and the finding has been associated mainly with suppression of transcriptional activity of the hepcidin gene. Iron overload has been associated with oxidative stress, advanced fibrosis and decreased survival, and promising therapies beyond phlebotomy and oral iron chelation have included hepcidin agonists. CONCLUSIONS:Iron dysregulation is common in chronic liver diseases other than hereditary haemochromatosis, and has been associated with liver toxicity and poor prognosis. Further evaluation of iron overload as a co-morbid factor should identify the key pathogenic disturbances, establish the risk threshold for irontoxicity, and promote molecular interventions.
Authors: Jérémy Dana; Aïna Venkatasamy; Antonio Saviano; Joachim Lupberger; Yujin Hoshida; Valérie Vilgrain; Pierre Nahon; Caroline Reinhold; Benoit Gallix; Thomas F Baumert Journal: Hepatol Int Date: 2022-02-09 Impact factor: 9.029
Authors: Anna Hernández-Aguilera; Núria Casacuberta; Helena Castañé; Montserrat Fibla; Salvador Fernández-Arroyo; Isabel Fort-Gallifa; Marta París; Fàtima Sabench; Daniel Del Castillo; Gerard Baiges-Gaya; Elisabet Rodríguez-Tomàs; Teresa Sans; Jordi Camps; Jorge Joven Journal: Biol Trace Elem Res Date: 2021-02-08 Impact factor: 3.738
Authors: Punnoth Poonkuzhi Naseef; Muhammed Elayadeth-Meethal; K T Mohammed Salim; A Anjana; C Muhas; K Abdul Vajid; Mohamed Saheer Kuruniyan Journal: Saudi J Biol Sci Date: 2021-12-13 Impact factor: 4.052